Aethlon Medical, Inc. (NASDAQ: AEMD) is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.
Co-Diagnostics, Inc. (Nasdaq: CODX) Leads Nasdaq Top Gainers on new Saudi-based CoMira Diagnostics joint venture |
Pharma Stock SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) Makes Nasdaq Top Gainer on News of Commercial Sales and Fulfillment of First Orders for Arbli |
Biotech Stock Artiva Biotherapeutics (Nasdaq: ARTV) Soars on News FDA has granted Fast Track Designation to AlloNK |
Rani Therapeutics (Nasdaq: RANI) Makes Nasdaq Top Gainer on $1.085 Billion Pharma Collaboration News |
Gene Therapy Stock Genprex, Inc. (NASDAQ: GNPX) Makes Nasdaq Top Gainers List on News of Positive Preclinical Data on the Use of Reqorsa |
Biotech and Medical Tech Stocks to Watch - Big Moves Following Clinical Trial News |
Medical Tech Stock Aethlon Medical's (NASDAQ: AEMD) Australian Oncology Clinical Trial Update and Progress |
Medtech Stocks - How a a company's IP portfolio Creates Market Leaders |
Medical Tech Stock Aethlon Medical (Nasdaq: AEMD) Announces Issuance of Hemopurifier Patents for the Treatment of Long COVID and COVID-19-associated Coagulopathy (CAC) |
Medical Tech Stock Aethlon Medical (Nasdaq: AEMD) Fiscal First Quarter Results Ending June 30, 2025, and Corporate Update |
First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.
iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.
iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.
iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.
iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.
Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.
Why Every Growing Dental Practice Needs a Specialized CPA for Dentists to Maximize Profits - November 7, 2025
4 Best Public Health Outcomes from Using Pigeon Contraceptives - September 22, 2025
Are All Workplace Breathalyzer Results Truly Defensible in Court? - August 27, 2025
How Flo Health's Pass It On Project Reaches Women Traditional Healthcare Can't - August 21, 2025
15 Features That Every Telehealth App Should Have for Both Patients and Doctors - February 19, 2025
Choosing the Right Dosage Form: Tablets, Capsules, or Liquids - January 30, 2025
Are Biohazard Remediation Services Worth Investing In? - November 29, 2024
Unleash Your Potential: Mojo Trek's Personalized Approach to Healthtech Recruitment - November 29, 2024
The Intersection of Business and Public Health: Why an MBA is Essential for Health Administrators - July 25, 2024
Nick Oberheiden and the Impella Heart Pump Cases - June 28, 2024
An Investor's Guide to Qualitative Analysis of Biotech Firms - June 18, 2024
How Healthcare Bookkeeping Services Elevate Your Business - March 27, 2024
The Rise of Mobile Applications in Healthcare and Medicine - September 5, 2023
How to Prove Wrongful Death - February 1, 2022
Healthcare Supply Chain Management Software - November 29, 2021
Overview of Biotech Stocks - What Could Happen by the End of 2021? - November 3, 2021
Consider Investing In These Disruptive Medical Companies In 2021 - April 16, 2021
Resources for Physicians and Medical Practices - December 31, 2020
Lockdown Part 2: The South African Economy and the Rand - December 15, 2020
How to Get Into Canada during COVID - November 30, 2020
The Impact of Gynecomastia on Your Mental Health and How to Deal With the Condition - September 8, 2020
Does Income Protection Cover Me for a COVID Redundancy? - August 10, 2020
Everything You Need to Know About Investing in Healthcare Stocks - March 30, 2020
The Rise Of The At-Home Testing Market - January 16, 2020
Why Do You Need Birth Injury Lawyer and How They Can Help You? - October 2, 2019
Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762 |
Impact Fusion International Inc. is Pleased to Announce That the " Florida Statewide Organization (FSO) of Omega Psi Phi Fraternity, Inc.," Has Created an Agricultural Committee to Test Impact Fusion's Proprietary Technology Against Citrus Greening, Citrus Canker, Increase Fruit Tree Yield, Increase Chicken Egg Production, and Producing Quality Beef Without New World Screwworms Infections With a Targeted Effort to Decrease Food Insecurity |
Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program |
BioHarvest Sciences Announces Pricing of $17.4 Million Upsized Public Offering of Common Stock |
Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases |
Subscribe to Biotech News RSS